Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Gianni Ghetti"'
Autor:
Edoardo Mannucci, Gianni Ghetti
Publikováno v:
Farmeconomia: Health Economics and Therapeutic Pathways, Vol 23, Iss 1 (2022)
BACKGROUND: Cardiovascular diseases represent the main cause of mortality and morbidity in type 2 diabetes mellitus (T2DM) patients. Empagliflozin is used as a treatment for T2DM because of its association with reduced risk of hospitalization for hea
Externí odkaz:
https://doaj.org/article/a87b113c3c5a4b53841b28ca3af2fbfe
Autor:
Paolo Castagno, Simone Pernice, Gianni Ghetti, Massimiliano Povero, Lorenzo Pradelli, Daniela Paolotti, Gianfranco Balbo, Matteo Sereno, Marco Beccuti
Publikováno v:
BMC Bioinformatics, Vol 21, Iss S8, Pp 1-32 (2020)
Abstract Background Emerging and re-emerging infectious diseases such as Zika, SARS, ncovid19 and Pertussis, pose a compelling challenge for epidemiologists due to their significant impact on global public health. In this context, computational model
Externí odkaz:
https://doaj.org/article/507104d11ad241ad8d1708e0ccb7a53c
Autor:
Stefan Schraag, Lorenzo Pradelli, Abdul Jabbar Omar Alsaleh, Marco Bellone, Gianni Ghetti, Tje Lin Chung, Martin Westphal, Sebastian Rehberg
Publikováno v:
BMC Anesthesiology, Vol 18, Iss 1, Pp 1-9 (2018)
Abstract Background It is unclear if anaesthesia maintenance with propofol is advantageous or beneficial over inhalational agents. This study is intended to compare the effects of propofol vs. inhalational agents in maintaining general anaesthesia on
Externí odkaz:
https://doaj.org/article/d9f21499f61940fcb8e9ee4b21921d8d
Publikováno v:
Farmeconomia: Health Economics and Therapeutic Pathways, Vol 20, Iss 1 (2019)
BACKGROUND: Although the use of long-acting injectable antipsychotics (LAIs) is considered an important option in the management of schizophrenia two recent meta-analysis, which aimed to compare LAIs vs oral antipsychotics (OAPs) in terms of relapse
Externí odkaz:
https://doaj.org/article/386e897cbca94d7da7a737f4749b3c93
Autor:
Lorenzo Pradelli, Gianni Ghetti
Publikováno v:
Farmeconomia: Health Economics and Therapeutic Pathways, Vol 18, Iss 1 (2017)
We developed a general model for estimating and comparing disease- and treatment-specific lost paid/unpaid production (due to premature death and reduced ability) and informal care received (due to reduced ability) in Italy, starting from survival, d
Externí odkaz:
https://doaj.org/article/22ee640a0a7942bb8e5a7fb9950e387e
Autor:
Nicola Parenti, Diego Sangiorgi, Gianfranco Cervellin, Roberta Petrino, Gianni Rastelli, Gianni Ghetti, Mario Cavazza
Publikováno v:
Emergency Care Journal, Vol 9, Iss 2, Pp e20-e20 (2013)
In Italy there are many triage guidelines and methods based on consensus. But, to our knowledge, there are few data on the reliability and predictive validity of triage systems adopted by Italian emergency departments. The Triage Emergency Method ver
Externí odkaz:
https://doaj.org/article/556a828122794958be4cecc7785ba112
Autor:
Gianni Ghetti, Massimiliano Povero
Publikováno v:
Value in Health.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c78ddffa40a543f17eebaed81482f6b7
https://doi.org/10.1016/j.jval.2023.03.012
https://doi.org/10.1016/j.jval.2023.03.012
Publikováno v:
ClinicoEconomics and Outcomes Research.
Gianni Ghetti,1 Lorenzo Pradelli,1 Giannis Papageorgiou,2 George Karpouzos,2 Yelda Arikan3 1AdRes Health Economics and Outcome Research, Turin, Italy; 2Boehringer Ingelheim Hellas, Athens, Greece; 3Boehringer Ingelheim, Amsterdam, the NetherlandsCorr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::182ebc2f68aa21f22cd3894b46106641
https://www.dovepress.com/celestia-cost-effectiveness-analysis-of-empagliflozin-versus-sitaglipt-peer-reviewed-fulltext-article-CEOR
https://www.dovepress.com/celestia-cost-effectiveness-analysis-of-empagliflozin-versus-sitaglipt-peer-reviewed-fulltext-article-CEOR
Autor:
Alice Sabinot, Gianni Ghetti, Lorenzo Pradelli, Stefania Bellucci, Antonella Lausi, Giovanni Palladini
Publikováno v:
Blood Reviews. 59:101040
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d49d17218e8908baf25df41f79928d02
https://doi.org/10.1016/j.blre.2023.101040
https://doi.org/10.1016/j.blre.2023.101040
Publikováno v:
ClinicoEconomics and Outcomes Research: CEOR
Gianni Ghetti,1 Maria Claudia D’Avella,2 Lorenzo Pradelli1 1Department of Health Economics and Outcome Research, AdRes, Turin, Italy; 2Department of Market Access, Sanofi, Milan, ItalyCorrespondence: Gianni GhettiDepartment of Health Economics and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51bcd7ee5d5669d702a151e9214a4c37
https://doi.org/10.2147/ceor.s295605
https://doi.org/10.2147/ceor.s295605